Which class of antibody drugs does Datopotamab belong to?

Datopotamab (Datopotamab) is a new type of antibody drug conjugate (ADC). Antibody drug conjugates are a class of therapeutic drugs that combine targeted antibodies and cytotoxic drugs to improve the precision and efficacy of cancer treatment. The working principle of ADC is to combine a potent cytotoxic drug with an antibody through a chemical linker. After using the antibody to recognize and bind to specific antigens on the surface of cancer cells, the toxic drug is directly delivered into the tumor cells to achieve precise treatment effects.

The mechanism of action of dabrotuzumab is based on this technology. It consists of an anti-HER2 antibody and the chemical toxin deruxtecan, which can precisely target HER2-negative cancer cells. In this way, dabrotomab can effectively reduce damage to normal cells while delivering a lethal blow to cancer cells.

As an antibody-drug conjugate, the advantage of dabrotuzumab is that it can not only target the HER2 antigen on the surface of cancer cells through antibodies, thereby increasing the accumulation of the drug in cancer cells, but it can also directly kill cancer cells through its cytotoxic part. Therefore, it provides a new treatment option for cancer patients who have failed traditional treatments.

In short, dabrotomab, as an antibody drug conjugate (ADC), plays a unique role in cancer treatment by binding to antibodies to target cancer cells and release cytotoxic drugs, showing its broad application prospects in breast cancer, non-small cell lung cancer and other cancers. It provides new treatment options for patients who are ineffective with traditional treatments, improves patients' quality of life, and prolongs survival to a certain extent.

Reference materials:https://www.drugs.com/mtm/datopotamab-deruxtecan.html